NovoCure

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

CEO

Frank Leonard

CEOFrank Leonard

Employees

1,605

Employees1,605

Headquarters

St. Helier, Jersey

HeadquartersSt. Helier, Jersey

Founded

2000

Founded2000

Employees

1,605

Employees1,605

NVCR Key Statistics

Market cap

1.99B

Market cap1.99B

Price-Earnings ratio

-11.21

Price-Earnings ratio-11.21

Dividend yield

—

Dividend yield—

Average volume

2.05M

Average volume2.05M

High today

$17.31

High today$17.31

Low today

$15.61

Low today$15.61

Open price

$15.87

Open price$15.87

Volume

1.88M

Volume1.88M

52 Week high

$18.92

52 Week high$18.92

52 Week low

$9.82

52 Week low$9.82

Stock Snapshot

NovoCure(NVCR) stock is priced at $17.20, giving the company a market capitalization of 1.99B. It carries a P/E multiple of -11.21.

On 2026-07-03, NovoCure(NVCR) stock traded between a low of $15.61 and a high of $17.31. Shares are currently priced at $17.20, which is +10.2% above the low and -0.6% below the high.

NovoCure(NVCR) shares are trading with a volume of 1.88M, against a daily average of 2.05M.

During the past year, NovoCure(NVCR) stock moved between $9.82 at its lowest and $18.92 at its peak.

NVCR News

Nasdaq 2d

NovoCure's Cancer Treatment Device Option Pax Gets European Approval

NovoCure Limited NVCR recently announced that its portable medical device, Option Pax, has received the CE (Conformité Européenne) mark for treating adult patie...

CNN 3d

symbol__ Stock Quote Price and Forecast - CNN

...

TipRanks 4d

Novocure’s Optune Pax Secures CE Mark for Pancreatic Cancer

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

28.6%

Sell

More NVCR News

TipRanks 4d

Novocure announces Optune Pax received CE Mark

Novocure (NVCR) announced that Optune Pax has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, c...

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.